Grant H Skrepnek, PhD
Associate Professor; Investigator, VIPER Institute
Department:
Pharmacy Practice and Science
(520) 626-3930
Fax:
(520) 626-7355
E-mail:
Location:
Pharmacy 316
Bio / Research:
Introduction
Grant H. Skrepnek, PhD, RPh, is an assistant professor in the Department of Pharmaceutical Sciences and in the Department of Pharmacy Practice and Science at The University of Arizona College of Pharmacy, and additionally serves as an investigator within The Center for Health Outcomes and PharmacoEconomic Research. Dr. Skrepnek received his BS, MS, and PhD in pharmacy at The University of Texas at Austin, completing his doctoral minor area studies in finance and his master’s minor area studies in management.
Research
As faculty at The University of Arizona, Dr. Skrepnek’s research agenda broadly involves pharmaceutical economics, policy, and outcomes. From a clinical stance, Dr. Skrepnek focuses upon pharmacoeconomics and outcomes within oncologic, cardiovascular, pulmonary, endocrine, mental health, infectious diseases. Furthermore, he is engaged in advancing the methodological and statistical approaches used within assessments of health technology. His interests extend to policy issues concerning Schumpeterian and industrial organization economics, strategic management, financial asset valuation, and technological change in the pharmaceutical industry. In particular, he has conducted research involving mergers and acquisitions, risk and return of pharmaceutical research and development, firm-level determinants and valuation of innovative activity within the drug sector, the commercialization of biotechnology, venture capital, and the econometrics of the financial markets. Dr. Skrepnek also studies practice-related aspects of pharmacy which include drug safety, patient compliance and adherence, disease management, and the use of technology by clinicians. He has received funding from numerous organizations and is an ongoing co-investigator within The University of Arizona's Center for Education and Research on Therapeutics (CERT) drug-drug interactions core funded by the Agency for Healthcare Research and Quality (AHRQ).
Teaching
Currently, Dr. Skrepnek teaches and coordinates PHPR 842 (Professional Practice Management) in the PharmD curriculum, which surveys principles of pharmacoeconomics, corporate finance, leadership, and organizational behavior. Within the graduate program, he teaches PHSC 513 (Health Technology Assessment) and PHSC 544 (Pharmaceutical Policy). The student research supervision that Dr. Skrepnek has been engaged in as an advisor or committee member spans almost 50 PharmD, MS, or PhD candidates. He has delivered more than 50 professional presentations which include research podiums, continuing medical and pharmacy education, and executive training programs.
Service
Dr. Skrepnek is actively engaged in service, and is involved in numerous committees and positions. He is the advisor to Phi Lambda Sigma Leadership Society, co-advisor to the Kappa Psi Fraternity, and is a member of the honor societies of Phi Kappa Phi and Rho Chi. He serves in the position of editor for the peer-reviewed journal Current Medical Research and Opinion® (CMRO) and is an ad hoc reviewer for numerous scientific journals. In 2005, CMRO’s publishing group received a Queen’s Award for Enterprise in International Trade, which has been denoted as the United Kingdom’s most prestigious award for business performance. He additionally has served as a consultant to numerous organizations and is a member of Standard & Poor’s Society of Industry Leaders and Gerson Lehrman Group’s Healthcare Council.
Areas of Expertise:
Pharmacoeconomics and Health Outcomes
Cost-effectiveness analysis; Database analysis; Decision-analytic modeling; Advanced methodology and mathematical statistics
Therapeutic areas:
Cardiovascular--Heart failure; Dyslipidemia; Coronary artery disease; Hypertension; Peripheral arterial occlusions; Anticoagulation
CNS/Mental Health--Major depressive disorder; Schizophrenia
Endocrine--Diabetes
Infectious Disease--Community-acquired pneumonia; Hepatitis C
Pulmonary--Asthma; Chronic obstructive pulmonary disease
Oncology--Chronic myelogenous leukemia; Ovarian cancer; Bone marrow transplantation; Glioblastoma multiforme; Grade III and IV adverse events
Financial Economics and Industrial Organization
Pharmaceutical economics and policy; Profitability measurement; Mergers and acquisitions; Asset valuation; Capital markets; Risk and return of pharmaceutical R&D; Competitive strategy; Venture capital; Biotechnology; Business cycles
Pharmacy Practice and Management Science
Drug safety (medication errors, risk management, and drug-drug interactions); Compliance and adherence; Disease management; Information systems
BS, The University of Texas at Austin, 1994
MS, The University of Texas at Austin, 1998
PhD,The University of Texas at Austin, 2002
Skrepnek GH. The Contrast and Convergence of Bayesian and Frequentist Approaches in Pharmacoeconomic Analyses. PharmacoEconomics 2007 [In press].
Skrepnek GH, Sarnowski JJ. Decision-Making Associated with Drug Candidates in the Biotechnology Research and Development (R&D) Pipeline. Journal of Commercial Biotechnology 2007 [In press].
Elliot WJ, Plauschinat CA, Skrepnek GH, Gausse D. Persistence, Compliance, and Risk of Discontinuation Associated with Commonly Prescribed Antihypertensive Drug Monotherapy. Journal of the American Board of Family Medicine 2007;20:72-80.
Ventura D, Armstrong EP, Skrepnek GH, Erder MH. Escitalopram versus Sertraline in the Treatment of Major Depressive Disorder: A Randomized Comparative Clinical Trial. Current Medical Research and Opinion 2007;23:245-250.
Armstrong EP, Skrepnek GH, Erder MH. Cost-Utility Comparison of Escitalopram and Sertraline in the Treatment of Major Depressive Disorder. Current Medical Research and Opinion 2007;23:251-258.
Hess LM, Benham-Hutchins M, Herzog TJ, Hsu P, Malone DC, Skrepnek GH, Slack MK, Alberts DS. A Meta-analysis of the Efficacy of Intraperitoneal versus Intravenous Cisplatin-based Chemotherapy Regimens for the Front-line Treatment of Ovarian Cancer. International Journal of Gynecological Cancer 2007 [In press].
Yeh D, Armstrong EP, Skrepnek GH, Malone DC. A Cost-utility Analysis of Pegylated Interferons in the Treatment of Hepatitis C. Pharmacotherapy 2007 [In press].
Plaza CM, Draugalis JR, Slack MK, Skrepnek GH, Sauer KA. Use of Curriculum Mapping in Program Assessment and Evaluation. American Journal of Pharmaceutical Education 2007 [In press].
Plaza CM, Draugalis JR, Slack MK, Skrepnek GH, Sauer KA. The Use of Reflective Portfolios in Health Sciences Education: A Literature Review and Factors to Consider. American Journal of Pharmaceutical Education 2007 [In press].
Mahmood M, Malone DC, Abarca J, Armstrong EP, Skrepnek GH, Murphy JE, Grizzle AJ, Ko Y, Woosley RL. Assessment of Potential Drug-Drug Interactions within Veterans Affairs Medical Centers. American Journal of Health-Systems Pharmacy 2007 [In press].
Malone DC, Abarca J, Skrepnek GH, Murphy JE, Armstrong EP, Rehfeld RA, Woosley RL. Pharmacist Workload and Pharmacy Characteristics Associated with the Dispensing of Clinically Important Drug-Drug Interactions. Medical Care 2007 [In press].
Skrepnek GH, Fishman JC, Yancy ML. The Relative Performance of Pharmaceutical Sector Security Prices During Stock Market Crashes. [Abstract] Value in Health 2007.
Ko Y, Malone DC, D’Agostino JV, Skrepnek GH, Armstrong EP, Brown M, Rehfeld RA, Abarca J, Woosley RL. An Application of Item Response Theory to Prescribers’ Knowledge and Attitude Measurement. [Abstract] Value in Health 2007.
Ko Y, Malone DC, Skrepnek GH, Armstrong EP, Murphy JE, Abarca J, Rehfeld RA, Reel SJ, Woosley RL. A National Survey on Prescribers’ Knowledge of and Their Source of Drug-drug Interaction Information. [Abstract] Value in Health 2007.
Malone DC, Abarca J, Skrepnek GH, Murphy JE, Armstrong EP, Grizzle AJ, Rehfeld RA, Woosley RL. Pharmacist Workload and Pharmacy Characteristics Associated with the Dispensing of Potentially Clinically Important Drug-drug Interactions. [Abstract] Value in Health 2007.
Mahmood MH, Armstrong EP, Malone DC, Skrepnek GH. Examining the Association Between Exposure Rates to Clinically Important Drug-drug Interactions and Pharmaceutical Services within Ambulatory Care Settings in Veterans Affairs Medical Centers. [Abstract] Value in Health 2007.
Murphy JE, Malone DC, Skrepnek GH, Armstrong EP, Abarca J, Grizzle AJ, Rehfeld R, Woosley RL. The Role of Technicians in Managing Computerized Drug-drug Interaction Alerts in Community Pharmacies and the Relationship to Pharmacist Managers’ Attitudes. Journal of Pharmacy Technology 2006;22:155-160.
Abarca J, Malone DC, Skrepnek GH, Rehfeld RA, Murphy JE, Grizzle AJ, Armstrong EP, Woosley RL. Community Pharmacy Managers' Perception of Computerized Drug-drug Interaction Alerts. Journal of the American Pharmacists Association 2006;46(2):148-153.
Skrepnek GH, Armstrong EP, Malone DC, Abarca J, Murphy JE, Grizzle AJ, Rehfeld RA, Woosley RL. Workload and Availability of Technology in Metropolitan Community Pharmacies. Journal of the American Pharmacists Association 2006;46(2):154-160.
Skrepnek GH, Armstrong EP. An evaluation of a disease management program for schizophrenics in a Medicaid population. [Report] Denver, Colorado: Colorado Department of Health Care Policy and Financing; 2006.
Skrepnek GH, Skora J. Cost Estimates of Managing Grade III and IV Pleural Effusions, Pericardial Effusions, and Non-Variceal Gastrointestinal Hemorrhages in Cancer Patients. [Abstract] Blood 2006.
Olvey E, Skrepnek GH, Nolan P. A Decision-Analytic Model Comparing Urokinase versus Recombinant Tissue Plasminogen Activator in the Treatment of Peripheral Arterial Occulsions. [Abstract] Pharmacotherapy 2006.
Wang MT, Malone DC, Skrepnek GH, Armstrong EP, Sherrill D. An evaluation of the association between health care utilization and use of salmeterol among subjects with asthma. [Abstract] Value in Health 2006.
Skrepnek GH. Cost-Effectiveness Analysis. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of PharmacoEconomics. Third Edition. Cincinnati, Ohio: W Harvey Whitney Books Company [Chapter]; 2005:83-116.
Skrepnek GH, Bootman JL. Patient Safety and Medication Errors. Italian Journal of Public Health 2005;2(3-4):25-33
Skrepnek GH, Abarca J, Malone DC, Armstrong EP, Shirazi FM, Woosley RL. Incremental Effects of Concurrent Pharmacotherapeutic Regimens for Heart Failure on Hospitalizations and Costs. Annals of Pharmacotherapy 2005;39:1785-1791.
Skrepnek GH. The Cost-Effectiveness of HMG-CoA Reductase Inhibitors in the Treatment of Dyslipidemia and Prevention of Coronary Heart Disease (CHD). Expert Review in Pharmacoeconomics and Outcomes Research 2005;5:603-623.
Skrepnek GH. Regression Methods in the Empiric Analysis of Health Care Data. Journal of Managed Care Pharmacy 2005;11:240-251.
Skrepnek GH, Ballard EE. Cost-Efficacy of Imatinib versus Allogeneic Bone Marrow Transplantation with a Matched Unrelated Donor in the Treatment of Chronic Myelogenous Leukemia: A Decision-Analytic Approach. Pharmacotherapy 2005;25:325-334.
Skrepnek GH, Armstrong EP, Malone DC, Ramachandran S. An Economic and Clinical Assessment of First-Line Monotherapy in the Treatment of Community-Acquired Pneumonia within Managed Care. Current Medical Research and Opinion 2005;21:261-270.
Yeh WS, Skrepnek GH, Armstrong EP, Malone DC. A Comparison of Methods to Assess Quality of Life in Economic Analyses of Hepatitis C Treatments. [Abstract] Value in Health 2005.
Yaffe K, Skrepnek GH, Armstrong EP. An Evaluation of a Disease Management Program for Adult Diabetics in a Medicaid Population. [Abstract] Value in Health 2005.
Wang MT, Malone DC, Skrepnek GH, Armstrong EP. Introduction of Bias When Using the Smearing Re-Transformation Method in the Presence of Positively Skewed Anti-Logged Residuals. [Abstract] Value in Health 2005.
Yaffe K, Skrepnek GH, Armstrong EP. An evaluation of a disease management program for adult diabetics in a Medicaid population. [Report] Denver, Colorado: Colorado Department of Health Care Policy and Financing; 2005.
Skrepnek GH. Accounting versus Economic Rates of Return: Implications for Profitability Measures in the Pharmaceutical Industry. Clinical Therapeutics 2004;26:155-174.
Skrepnek GH, Skrepnek SV. Epidemiology, Clinical and Economic Burden, and Natural History of Chronic Obstructive Pulmonary Disease and Asthma. American Journal of Managed Care 2004;10s:129-138.
Skrepnek GH, Skrepnek SV. An Assessment of Therapeutic Regimens in the Treatment of Acute Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma. American Journal of Managed Care 2004;10s:139-152.
Plaza CM, Draugalis JR, Slack MK, Skrepnek GH. Administrative Career Planning: A Ten-Year Update of the Pharmacy Deanship. American Journal of Pharmaceutical Education 2004;68(1):1-8.
Plaza, CM, Draugalis JR, Skrepnek GH, Slack MK. Administrative Mentoring and Career Planning in the Pharmacy Deanship. American Journal of Pharmaceutical Education 2004;68(4):1-12.
Wang MT, Malone DC, Skrepnek GH, Armstrong EP. Evaluation of 25 clinically important drug-drug interactions using a managed care database. [Abstract] Pharmacotherapy 2004.
Skrepnek GH, Lawson KA. Stock Market Valuation and Firm-Level Determinants of Innovative Activity in the Pharmaceutical Industry. [Abstract] Value in Health 2004.
Skrepnek GH. Competitive Strategic Management Via Mergers and Acquisitions: Caveat Emptor? [Editorial] Tucson, Arizona: The University of Arizona, Center for Health Outcomes and PharmacoEconomic Research; 2003:3-4.
Lai L, Armstrong EP, French R, Salcido A, Skrepnek GH. Women’s Perception of Bone-Mineral Density Screening and Osteoporosis Education in the Community Pharmacy. The Consultant Pharmacist 2003;18:968-976.
Sahai A, Skrepnek GH, Abarca J. Hierarchical Confounding and Scientific Analysis: Statistical Issues for Randomized Controlled Trial Data. [Abstract] Portland, Maine: Proceedings of the International Conference on Statistics, Combinatorics and Related Areas. Symposium on Statistics in Health Policy Analysis and Health Care Research. University of Southern Maine; 2003.
Sahai A, Skrepnek GH, Malone DC. On Optimal Confidence Intervals for the Lognormal Mean. Proceedings of the International Conference on Statistics, Combinatorics and Related Areas. [Abstract] Portland, Maine: Proceedings of the International Conference on Statistics, Combinatorics and Related Areas. Symposium on Statistics in Health Policy Analysis and Health Care Research. University of Southern Maine; 2003.
Sahai A, Skrepnek GH, Joish VN. On Improved Confidence-Interval Estimation of Cost-Effectiveness Ratios. Proceedings of the International Conference on Statistics, Combinatorics and Related Areas. [Abstract] Portland, Maine: Proceedings of the International Conference on Statistics, Combinatorics and Related Areas, Symposium on Statistics in Health Policy Analysis and Health Care Research, University of Southern Maine; 2003.
Sahai A, Skrepnek GH, Armstrong EP, Malone DC. Using Logarithmic Transformation in Biomedical Research: Efficient Estimation of the Lognormal Mean. [Abstract] Portland, Maine: Proceedings of the International Conference on Statistics, Combinatorics and Related Areas, Symposium on Statistics in Health Policy Analysis and Health Care Research, University of Southern Maine; 2003.
Sahai A, Skrepnek GH. Meta-Analysis of Panel Data Generated by a Set of Randomized Controlled Trials. International Conference on Statistics, Combinatorics and Related Areas. [Abstract] Portland, Maine: Proceedings of the International Conference on Statistics, Combinatorics and Related Areas, Symposium on Statistics in Health Policy Analysis and Health Care Research, University of Southern Maine; 2003.
Skrepnek GH. Stock Market Valuation and Firm-Level Determinants of Innovative Activity in the Pharmaceutical Industry. [PhD Dissertation] Austin, Texas: The University of Texas at Austin; 2002:792 pages.
Zachry WM, Skrepnek GH. Applying Multiattribute Utility Technology to the Formulary Evaluation Process. Formulary 2002;38:199-206.
Skrepnek GH, Lawson KA. Measuring Changes in Capital Market Security Prices: The Event Study Methodology. Journal of Research in Pharmaceutical Economics 2001;11:1-17.
Skrepnek GH, Lawson KA. The Effect of Merger and Acquisition Activity on Shareholder Returns in the Pharmaceutical Industry. Journal of Research in Pharmaceutical Economics 2001;11:19-38.
Skrepnek GH. The Effect of Merger and Acquisition Activity on Shareholder Returns in the Pharmaceutical Industry. [Master’s Thesis] Austin, Texas: The University of Texas at Austin; 1998:213 pages.
Lawson KA, Johnsrud MT, Hong SH, Skrepnek GH. An Assessment of the Cost-Saving Options for the Texas Medicaid Vendor Drug Program. [Report] Austin, Texas: Texas Department of Health; 1995: 48 pages.